Provided by Tiger Fintech (Singapore) Pte. Ltd.

Terns Pharmaceuticals, Inc.

3.18
-0.2700-7.83%
Post-market: 3.250.0700+2.20%19:35 EDT
Volume:1.75M
Turnover:5.70M
Market Cap:270.11M
PE:-2.70
High:3.50
Open:3.49
Low:3.16
Close:3.45
Loading ...

Company Profile

Company Name:
Terns Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
66
Office Location:
1065 East Hillsdale Boulevard,Suite 100,Foster City,California,United States
Zip Code:
94404
Fax:
650 275 4254
Introduction:
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Directors

Name
Position
Senthil Sundaram
Chief Executive Officer and Director
Weidong Zhong
Chief Scientific Officer and Chairman
Carl Gordon
Director
David Fellows
Director
Hongbo Lu
Director
Jeffrey Kindler
Director
Jill Quigley
Director

Shareholders

Name
Position
Senthil Sundaram
Chief Executive Officer and Director
Bryan Yoon
Chief Operating Officer and General Counsel
Mark Vignola
Chief Financial Officer
Erin Quirk
President and Chief Medical Officer
Weidong Zhong
Chief Scientific Officer and Chairman